Ones To Watch News
Refine Search
Biotechnology
Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million. 23 January 2025
Pharmaceutical
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. 23 January 2025
Biotechnology
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. 23 January 2025
Biotechnology
US genetic meds company MeiraGTx Holdings yesterday revealed that the US Food and Drug Administration (FDA) has granted the company Rare Pediatric Disease (RPD) designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). 23 January 2025
Biotechnology
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange. 22 January 2025
Biotechnology
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesd
ay, having lost 41% of its stock market value on Friday. 22 January 2025
Biotechnology
Icelandic drug discovery and development company Arctic Therapeutics has announced the successful closing of a 26.5 million euros ($27.7 million) oversubscribed Series A financing from a broad syndicate of investors. 22 January 2025
Biotechnology
Kyverna Therapeutics (Nasdaq: KYTX), a California biotech developing CAR-T therapies for autoimmune diseases, has appointed Naji Gehchan as chief medical officer. 22 January 2025
Biotechnology
Oslo-based biotech Circio has entered into a partnership with UK-based 4basebio (AIM: 4BB) to develop and test synthetic “circVec” DNA vectors. 21 January 2025
Pharmaceutical
Swedish pharmaceutical company Orexo has converted its rights to future transaction proceeds and royalties from vipoglanstat into shares in Gesynta Pharma. 20 January 2025
Biotechnology
T-cell immunotherapy company Atara Biotherapeutics closed 41% lower on Friday. 17 January 2025
Biotechnology
OS Therapies has reported positive data from a Phase IIb trial evaluating OST-HER2, a HER2-targeted immunotherapy. 16 January 2025
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience saw its shares jump more than 13% to 0.26 kronor this morning, as it announced the positive outcome of regulatory interactions with the Paul Ehrlich Institute (PEI) of Germany and the US Food and Drug Administration (FDA) regarding the CMC development of mitazalimab, which is in development as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX. 16 January 2025
Pharmaceutical
UK clinical-stage specialty pharma firm Actimed Therapeutics has appointed Dr Fabio Dorigotti as chief medical officer (CMO) following the retirement of previous CMO, Dr Frank Misselwitz. 16 January 2025
Pharmaceutical
Cambridge, UK-based firm Owlstone Medical has raised $27 million in a series E funding round, led by Ventura Capital and supported by Aviva, Horizons, and others including the Gates Foundation. 15 January 2025
Biotechnology
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing. 14 January 2025
Pharmaceutical
US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS trial of linsitinib in patients with active, moderate to severe thyroid eye disease (TED). 14 January 2025
Biotechnology
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California. 14 January 2025
Biotechnology
US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced the achievement of a success milestone for one of the targets in its research collaboration with French pharma major Sanofi to develop in vivo CRISPR-based therapeutics. 14 January 2025
Pharmaceutical
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have unveiled Phase II trial data for their obesity drug HRS9531, a GLP-1/GIP receptor dual agonist. 14 January 2025
Biotechnology
Precision oncology start-up Fore Biotherapeutics, founded in 2011, today announced a $38 million Series D-2 financing. 22 May 2025
Pharmaceutical
USA-based UroGen Pharma, a biotech developing and commercializing innovative solutions that treat urothelial and specialty cancers, closed 45% lower Wednesday. 22 May 2025
Biotechnology
Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration with Genentech, a subsidiary of Roche , to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology. 22 May 2025
Pharmaceutical
Swiss reproductive and women’s health medicines specialist ReproNovo today announced the successful closing of a $65 million Series A financing round, which will be used to advance its pipeline of multiple Phase II programs. 21 May 2025
Pharmaceutical
North Carolina, USA-based vTv Therapeutics has announced that screening has been reinitiated in the company’s CATT1 Phase III trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). 21 May 2025
Biotechnology
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
Biotechnology
UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. 21 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Pharmaceutical
Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults living with mild, moderate and severe OSA, and across all weight classes. 20 May 2025
Biotechnology
German vaccine pioneer BioNTech today revealed that its UK subsidiary has signed a grant agreement with the UK government to broaden the company’s R&D activities for innovative medicines in the UK. 20 May 2025
Biotechnology
Swiss gene-editing specialist CRISPR Therapeutics and San Diego, USA-based Sirius Therapeutics, which is developing innovative small interfering RNA (siRNA) therapies, announced a strategic partnership to develop and commercialize siRNA therapies. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biotechnology
Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round. 19 May 2025
Biotechnology
US human genetics biotech 23andMe today revealed it has entered into a definitive agreement for the sale of the company to Regeneron Pharmaceutical, whose shares climbed 2% following the announcement 19 May 2025
Pharmaceutical
USA-based rare disease company Applied Therapeutics saw its shares rise nearly 23% to $0.60 on Friday, ahead of a planned presentation on its lead candidate, govorestat, at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20 in Edinburgh, Scotland. 19 May 2025
Biotechnology
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Biotechnology
Telomir Pharmaceuticals, a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. 16 May 2025
Pharmaceutical
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze